Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

This publication has 15 references indexed in Scilit:

• The endocannabinoid system in obesity and type 2 diabetes
  Diabetologia, 2008
• Targeting the endocannabinoid system: to enhance or reduce?
  Nature Reviews Drug Discovery, 2008
• Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes
  Nature Reviews Molecular Cell Biology, 2008
• Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †
  European Heart Journal, 2008
• Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients
  Diabetes Care, 2008
• Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Efficacy
  The American Journal of Cardiology, 2007
• The link between abdominal obesity, metabolic syndrome and cardiovascular disease
  Nutrition, Metabolism and Cardiovascular Diseases, 2007
• Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men
  International Journal of Obesity, 2007
• Abdominal obesity and metabolic syndrome
  Nature, 2006
• Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
  Diabetes, 2006